Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Maria Spiliotaki"'
Autor:
Maria Spiliotaki, Christiana Michael Neophytou, Paris Vogazianos, Ioannis Stylianou, Gregoria Gregoriou, Andreas Ioannou Constantinou, Constantinos Deltas, Haris Charalambous
Publikováno v:
Molecular Oncology, Vol 17, Iss 5, Pp 792-809 (2023)
Programmed cell death protein ligand‐1 (PD‐L1) expression in non‐small cell lung cancer (NSCLC) tumors guides treatment selection. PD‐L1 expression in circulating tumor cells (CTCs) may provide further information. We have explored PD‐L1 an
Externí odkaz:
https://doaj.org/article/b6d5bebc1cc44aff98b33c04b9a11d94
Autor:
Chara Papadaki, Michalis Stratigos, Georgios Markakis, Maria Spiliotaki, Georgios Mastrostamatis, Christoforos Nikolaou, Dimitrios Mavroudis, Sofia Agelaki
Publikováno v:
Breast Cancer Research, Vol 24, Iss 1, Pp 1-1 (2022)
Externí odkaz:
https://doaj.org/article/8e9e70f6dea44981931ed1679bf005b8
Autor:
Chara Papadaki, Michalis Stratigos, Georgios Markakis, Maria Spiliotaki, Georgios Mastrostamatis, Christoforos Nikolaou, Dimitrios Mavroudis, Sofia Agelaki
Publikováno v:
Breast Cancer Research, Vol 20, Iss 1, Pp 1-17 (2018)
Abstract Background In primary breast cancer metastases frequently arise from a state of dormancy that may persist for extended periods of time. We investigated the efficacy of plasma micro-RNA (miR)-21, miR-23b, miR-190, miR-200b and miR-200c, relat
Externí odkaz:
https://doaj.org/article/d52fe1ebaa4247a2afeb0f7ee8082013
Autor:
Maria Spiliotaki, Dimitris Mavroudis, Maria Kokotsaki, Eleni‐Kyriaki Vetsika, Ioannis Stoupis, Alexios Matikas, Galatea Kallergi, Vassilis Georgoulias, Sofia Agelaki
Publikováno v:
Molecular Oncology, Vol 12, Iss 1, Pp 21-32 (2018)
In patients with breast cancer, markers of aggressiveness such as dysregulation of the insulin‐like growth factor receptor (IGF1R) system and E‐cadherin loss are commonly observed. Reduced IGF1R expression is correlated with decreased E‐cadheri
Externí odkaz:
https://doaj.org/article/fa2cbd75940a4177bc150d31c54ace40
Autor:
Eleni Politaki, Sofia Agelaki, Stella Apostolaki, Dora Hatzidaki, Areti Strati, Filippos Koinis, Maria Perraki, Georgia Saloustrou, Giannis Stoupis, Galatea Kallergi, Maria Spiliotaki, Tereza Skaltsi, Evi Lianidou, Vassilis Georgoulias, Dimitrios Mavroudis
Publikováno v:
Cellular Physiology and Biochemistry, Vol 44, Iss 2, Pp 594-606 (2017)
Background: We directly compared CTC detection rates and prognostic significance, using three different methods in patients with breast cancer (BC). Methods: Early (n=200) and metastatic (n=164) patients were evaluated before initiating adjuvant or f
Externí odkaz:
https://doaj.org/article/4eae5b5e36454cabaa6fc93765049557
Autor:
Maria Spiliotaki, Christiana Michael Neophytou, Paris Vogazianos, Ioannis Stylianou, Gregoria Gregoriou, Andreas Ioannou Constantinou, Constantinos Deltas, Haris Charalambous
Publikováno v:
Molecular Oncology. 17:792-809
Programmed cell death protein ligand-1 (PD-L1) expression in non-small cell lung cancer (NSCLC) tumors guides treatment selection. PD-L1 expression in circulating tumor cells (CTCs) may provide further information. We have explored PD-L1 and marker o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92b9cfb8ebd1614e1bd70f665dae2e9e
https://doi.org/10.1002/1878-0261.13317
https://doi.org/10.1002/1878-0261.13317
Autor:
null Maria Spiliotaki, null Christiana Michael Neophytou, null Paris Vogazianos, null Ioannis Stylianou, null Gregoria Gregoriou, null Andreas Ioannou Constantinou, null Constantinos Deltas, null Haris Charalambous
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c197607f6810c7da8048e8e855d69a82
https://doi.org/10.1002/1878-0261.13317/v2/response1
https://doi.org/10.1002/1878-0261.13317/v2/response1
Autor:
Nefeli Georgoulia, Nikolaos Tsoukalas, Maria Spiliotaki, Galatea Kallergi, Filippos Koinis, Eleni Politaki, Dora Hatzidaki, Nikolaos Xenidis, Vassilis Georgoulias, Stella Apostolaki, A. Kotsakis, Christos Nikolaou
Publikováno v:
Cancer Chemotherapy and Pharmacology. 87:277-287
Detection of CTCs represents a poor prognostic factor in patients with early and metastatic breast cancer (mBC) and treatment with everolimus–exemestane (E/E) is an established effective treatment in hormone receptor-positive/HER2-negative mBC pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ddcb1068e7c77d3ef40e4c508b02bf9e
https://doi.org/10.1007/s00280-020-04227-5
https://doi.org/10.1007/s00280-020-04227-5
Autor:
Galatea Kallergi, Eleni-Kyriaki Vetsika, Alexios Matikas, Maria Spiliotaki, Ioannis Stoupis, Vassilis Georgoulias, Dimitris Mavroudis, Maria Kokotsaki, Sofia Agelaki
Publikováno v:
Molecular Oncology
Molecular Oncology, Vol 12, Iss 1, Pp 21-32 (2018)
Molecular Oncology, Vol 12, Iss 1, Pp 21-32 (2018)
In patients with breast cancer, markers of aggressiveness such as dysregulation of the insulin-like growth factor receptor (IGF1R) system and E-cadherin loss are commonly observed. Reduced IGF1R expression is correlated with decreased E-cadherin leve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0ab0fc7ee8c570470f5392629cf2e5b
http://europepmc.org/articles/PMC5748482
http://europepmc.org/articles/PMC5748482
Autor:
Giannis Stoupis, Maria Spiliotaki, Dimitrios Mavroudis, Stella Apostolaki, M. Perraki, Vassilis Georgoulias, Filippos Koinis, Eleni Politaki, Galatea Kallergi, Evi Lianidou, Georgia Saloustrou, Dora Hatzidaki, Areti Strati, Tereza Skaltsi, Sofia Agelaki
Publikováno v:
Cellular Physiology and Biochemistry, Vol 44, Iss 2, Pp 594-606 (2017)
Background: We directly compared CTC detection rates and prognostic significance, using three different methods in patients with breast cancer (BC). Methods: Early (n=200) and metastatic (n=164) patients were evaluated before initiating adjuvant or f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50b142f629575decf680ea57172c3aff
https://doi.org/10.1159/000485115
https://doi.org/10.1159/000485115